Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Neoplasms | 27 | 2024 | 713 | 3.760 |
Why?
|
Bone Neoplasms | 23 | 2024 | 2511 | 1.420 |
Why?
|
Drug-Eluting Stents | 5 | 2021 | 757 | 0.870 |
Why?
|
Fractures, Spontaneous | 7 | 2024 | 230 | 0.860 |
Why?
|
Sirolimus | 6 | 2021 | 1534 | 0.830 |
Why?
|
Peripheral Arterial Disease | 9 | 2024 | 1294 | 0.820 |
Why?
|
Cardiovascular Agents | 4 | 2021 | 866 | 0.820 |
Why?
|
Spinal Cord Compression | 3 | 2019 | 234 | 0.790 |
Why?
|
Coronary Artery Disease | 6 | 2024 | 6591 | 0.570 |
Why?
|
Epidural Abscess | 3 | 2023 | 92 | 0.510 |
Why?
|
Absorbable Implants | 4 | 2021 | 343 | 0.490 |
Why?
|
Coronary Restenosis | 3 | 2022 | 426 | 0.460 |
Why?
|
Postoperative Complications | 15 | 2021 | 15437 | 0.450 |
Why?
|
Angioplasty, Balloon | 3 | 2022 | 610 | 0.440 |
Why?
|
Soft Tissue Neoplasms | 4 | 2023 | 1149 | 0.430 |
Why?
|
Paclitaxel | 1 | 2019 | 1699 | 0.390 |
Why?
|
Spinal Fusion | 2 | 2019 | 1250 | 0.370 |
Why?
|
Sarcoma | 5 | 2018 | 1788 | 0.350 |
Why?
|
Limb Salvage | 2 | 2011 | 460 | 0.340 |
Why?
|
Femoral Artery | 4 | 2022 | 831 | 0.320 |
Why?
|
Orthopedic Procedures | 5 | 2020 | 1251 | 0.320 |
Why?
|
Stents | 2 | 2019 | 3298 | 0.320 |
Why?
|
Quality of Life | 7 | 2022 | 13153 | 0.320 |
Why?
|
MicroRNAs | 1 | 2024 | 3764 | 0.310 |
Why?
|
Chondrosarcoma | 2 | 2020 | 289 | 0.300 |
Why?
|
Femoral Neoplasms | 2 | 2017 | 81 | 0.280 |
Why?
|
Models, Molecular | 15 | 2008 | 5385 | 0.270 |
Why?
|
Retrospective Studies | 41 | 2024 | 79127 | 0.260 |
Why?
|
Salvage Therapy | 1 | 2011 | 1265 | 0.250 |
Why?
|
Algorithms | 8 | 2024 | 13900 | 0.240 |
Why?
|
Middle Aged | 56 | 2024 | 217019 | 0.230 |
Why?
|
Walking | 3 | 2022 | 1173 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 365 | 0.230 |
Why?
|
Liposarcoma, Myxoid | 1 | 2023 | 59 | 0.220 |
Why?
|
Treatment Outcome | 27 | 2023 | 64245 | 0.220 |
Why?
|
Humans | 98 | 2024 | 752341 | 0.210 |
Why?
|
Aged | 47 | 2024 | 166562 | 0.210 |
Why?
|
Atherectomy, Coronary | 1 | 2022 | 145 | 0.210 |
Why?
|
Extremities | 4 | 2023 | 854 | 0.200 |
Why?
|
Antiviral Agents | 7 | 2008 | 3032 | 0.200 |
Why?
|
Palliative Care | 1 | 2017 | 3573 | 0.200 |
Why?
|
Spine | 5 | 2020 | 1089 | 0.200 |
Why?
|
Molecular Weight | 2 | 2021 | 2182 | 0.200 |
Why?
|
Spinal Fractures | 2 | 2019 | 694 | 0.200 |
Why?
|
Liposarcoma | 1 | 2023 | 280 | 0.180 |
Why?
|
Hypoalbuminemia | 1 | 2021 | 86 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2022 | 9207 | 0.180 |
Why?
|
Neurosurgical Procedures | 4 | 2019 | 2023 | 0.180 |
Why?
|
Intermittent Claudication | 2 | 2012 | 306 | 0.180 |
Why?
|
Male | 58 | 2024 | 354881 | 0.180 |
Why?
|
Flaviviridae | 3 | 2008 | 9 | 0.180 |
Why?
|
Prosthesis Design | 3 | 2021 | 2121 | 0.170 |
Why?
|
Female | 56 | 2024 | 386053 | 0.170 |
Why?
|
Fracture Fixation, Internal | 2 | 2016 | 953 | 0.170 |
Why?
|
Lower Extremity | 5 | 2012 | 1184 | 0.160 |
Why?
|
Fibromatosis, Aggressive | 1 | 2020 | 124 | 0.160 |
Why?
|
Prospective Studies | 15 | 2022 | 53807 | 0.160 |
Why?
|
Cervical Atlas | 1 | 2018 | 22 | 0.160 |
Why?
|
Atherectomy | 2 | 2021 | 41 | 0.160 |
Why?
|
Iliac Artery | 1 | 2020 | 344 | 0.160 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 113 | 0.160 |
Why?
|
Lordosis | 1 | 2019 | 88 | 0.150 |
Why?
|
Chondroblastoma | 1 | 2018 | 48 | 0.150 |
Why?
|
Genetic Markers | 1 | 2024 | 2605 | 0.150 |
Why?
|
Popliteal Artery | 2 | 2021 | 312 | 0.150 |
Why?
|
Bone Diseases | 1 | 2021 | 416 | 0.150 |
Why?
|
Mutation, Missense | 2 | 2006 | 2556 | 0.150 |
Why?
|
Lumbosacral Region | 1 | 2019 | 290 | 0.150 |
Why?
|
Osteosarcoma | 2 | 2020 | 888 | 0.150 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2020 | 377 | 0.140 |
Why?
|
Platelet Aggregation | 1 | 2020 | 797 | 0.140 |
Why?
|
Humeral Head | 1 | 2017 | 41 | 0.140 |
Why?
|
Reoperation | 5 | 2018 | 4256 | 0.140 |
Why?
|
Prognosis | 14 | 2024 | 29327 | 0.140 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2018 | 116 | 0.140 |
Why?
|
Acute Coronary Syndrome | 2 | 2020 | 2355 | 0.140 |
Why?
|
Lung Neoplasms | 6 | 2019 | 13165 | 0.140 |
Why?
|
Chemoprevention | 1 | 2019 | 326 | 0.140 |
Why?
|
Adult | 38 | 2024 | 216913 | 0.140 |
Why?
|
Leg Bones | 1 | 2016 | 19 | 0.140 |
Why?
|
Nomograms | 2 | 2016 | 238 | 0.140 |
Why?
|
Polymers | 2 | 2019 | 1610 | 0.140 |
Why?
|
Muramidase | 2 | 2006 | 168 | 0.140 |
Why?
|
Biomedical Technology | 1 | 2019 | 209 | 0.140 |
Why?
|
Mobility Limitation | 1 | 2020 | 402 | 0.140 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 841 | 0.140 |
Why?
|
Equipment and Supplies | 1 | 2019 | 275 | 0.130 |
Why?
|
Humerus | 1 | 2018 | 269 | 0.130 |
Why?
|
Risk Factors | 18 | 2024 | 73412 | 0.130 |
Why?
|
Serum Albumin | 2 | 2017 | 676 | 0.130 |
Why?
|
Silicon | 2 | 2006 | 142 | 0.130 |
Why?
|
Amides | 3 | 2007 | 450 | 0.130 |
Why?
|
Ligaments, Articular | 1 | 2018 | 300 | 0.130 |
Why?
|
Alkaline Phosphatase | 1 | 2019 | 863 | 0.130 |
Why?
|
RNA Viruses | 2 | 2007 | 110 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2006 | 2895 | 0.130 |
Why?
|
Injury Severity Score | 1 | 2019 | 1033 | 0.130 |
Why?
|
Multiple Trauma | 1 | 2018 | 370 | 0.130 |
Why?
|
Survival Rate | 8 | 2024 | 12746 | 0.130 |
Why?
|
Computer Simulation | 8 | 2008 | 6170 | 0.120 |
Why?
|
Membranes, Artificial | 2 | 2006 | 366 | 0.120 |
Why?
|
Fractures, Bone | 2 | 2018 | 2022 | 0.120 |
Why?
|
Physical Endurance | 1 | 2017 | 361 | 0.120 |
Why?
|
Arthroplasty | 1 | 2017 | 309 | 0.120 |
Why?
|
Pelvic Bones | 1 | 2016 | 271 | 0.120 |
Why?
|
Coronary Stenosis | 1 | 2020 | 816 | 0.120 |
Why?
|
Thymosin | 1 | 2013 | 47 | 0.110 |
Why?
|
Patient Selection | 4 | 2020 | 4238 | 0.110 |
Why?
|
Survival Analysis | 7 | 2024 | 10177 | 0.110 |
Why?
|
Antitubercular Agents | 3 | 2007 | 1361 | 0.110 |
Why?
|
Drug Delivery Systems | 3 | 2019 | 2213 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 884 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 2 | 2020 | 3177 | 0.110 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15676 | 0.110 |
Why?
|
Mortality | 3 | 2020 | 2884 | 0.110 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2017 | 327 | 0.110 |
Why?
|
Case-Control Studies | 4 | 2024 | 21841 | 0.100 |
Why?
|
Humeral Fractures | 1 | 2015 | 281 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2019 | 1546 | 0.100 |
Why?
|
Femoral Fractures | 1 | 2016 | 374 | 0.100 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 5839 | 0.100 |
Why?
|
Ankle Brachial Index | 1 | 2012 | 157 | 0.100 |
Why?
|
Antifungal Agents | 2 | 2007 | 711 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2024 | 4419 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4274 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2024 | 3512 | 0.100 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2017 | 612 | 0.100 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 91 | 0.100 |
Why?
|
Molecular Structure | 8 | 2007 | 1893 | 0.100 |
Why?
|
Internationality | 1 | 2017 | 988 | 0.090 |
Why?
|
Aged, 80 and over | 15 | 2021 | 58300 | 0.090 |
Why?
|
Awards and Prizes | 1 | 2015 | 359 | 0.090 |
Why?
|
Health Status Indicators | 1 | 2016 | 968 | 0.090 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 594 | 0.090 |
Why?
|
Advisory Committees | 1 | 2015 | 781 | 0.090 |
Why?
|
Imidazoles | 2 | 2007 | 1175 | 0.090 |
Why?
|
Endovascular Procedures | 1 | 2024 | 2058 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2023 | 2065 | 0.090 |
Why?
|
Joint Instability | 1 | 2018 | 792 | 0.090 |
Why?
|
Leg | 1 | 2015 | 1090 | 0.090 |
Why?
|
Models, Chemical | 3 | 2007 | 611 | 0.090 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13553 | 0.090 |
Why?
|
Pain Measurement | 2 | 2017 | 3463 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2064 | 0.090 |
Why?
|
Angioplasty | 1 | 2012 | 361 | 0.090 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 4861 | 0.090 |
Why?
|
RNA Helicases | 2 | 2007 | 145 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1970 | 0.090 |
Why?
|
Athletes | 1 | 2017 | 1095 | 0.080 |
Why?
|
Surgical Wound Infection | 2 | 2016 | 1499 | 0.080 |
Why?
|
Protein Precursors | 1 | 2013 | 1126 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2016 | 1302 | 0.080 |
Why?
|
England | 2 | 2021 | 515 | 0.080 |
Why?
|
Time Factors | 9 | 2021 | 39854 | 0.080 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3821 | 0.080 |
Why?
|
Pneumonectomy | 1 | 2015 | 1105 | 0.080 |
Why?
|
Neoplasms | 1 | 2017 | 21808 | 0.080 |
Why?
|
Umbelliferones | 1 | 2007 | 12 | 0.080 |
Why?
|
Picornaviridae | 1 | 2007 | 14 | 0.080 |
Why?
|
Adenine Nucleotides | 1 | 2008 | 111 | 0.080 |
Why?
|
Carcinoma | 1 | 2019 | 2340 | 0.080 |
Why?
|
Hyperthermia, Induced | 1 | 2011 | 413 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6501 | 0.080 |
Why?
|
Follow-Up Studies | 9 | 2024 | 39079 | 0.070 |
Why?
|
Histones | 1 | 2018 | 2566 | 0.070 |
Why?
|
Drug Design | 4 | 2008 | 1058 | 0.070 |
Why?
|
Candida glabrata | 1 | 2007 | 31 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2020 | 3160 | 0.070 |
Why?
|
Diabetic Angiopathies | 1 | 2012 | 821 | 0.070 |
Why?
|
Phenanthrolines | 1 | 2007 | 51 | 0.070 |
Why?
|
Knee | 1 | 2009 | 274 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2782 | 0.070 |
Why?
|
Lymphocyte Count | 2 | 2019 | 776 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 3 | 2007 | 1886 | 0.070 |
Why?
|
Area Under Curve | 2 | 2024 | 1613 | 0.070 |
Why?
|
Biocompatible Materials | 2 | 2006 | 1687 | 0.070 |
Why?
|
ROC Curve | 3 | 2024 | 3530 | 0.070 |
Why?
|
Platelet Count | 2 | 2019 | 774 | 0.070 |
Why?
|
Ischemia | 1 | 2015 | 1874 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2479 | 0.070 |
Why?
|
Endarterectomy, Carotid | 1 | 2011 | 552 | 0.070 |
Why?
|
Radiosurgery | 1 | 2016 | 1335 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1822 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2241 | 0.070 |
Why?
|
Keto Acids | 1 | 2005 | 34 | 0.070 |
Why?
|
Blotting, Southern | 1 | 2006 | 779 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5620 | 0.060 |
Why?
|
Preoperative Period | 2 | 2019 | 549 | 0.060 |
Why?
|
Piperazines | 2 | 2006 | 2486 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 357 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8538 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 2440 | 0.060 |
Why?
|
Myocytes, Cardiac | 1 | 2013 | 1630 | 0.060 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2006 | 165 | 0.060 |
Why?
|
Thermodynamics | 1 | 2006 | 593 | 0.060 |
Why?
|
Structure-Activity Relationship | 5 | 2008 | 3078 | 0.060 |
Why?
|
Candida albicans | 1 | 2007 | 373 | 0.060 |
Why?
|
Reproducibility of Results | 5 | 2023 | 19894 | 0.060 |
Why?
|
Carotid Stenosis | 1 | 2011 | 860 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1879 | 0.060 |
Why?
|
Brachytherapy | 1 | 2011 | 1241 | 0.060 |
Why?
|
Phosphonoacetic Acid | 1 | 2003 | 54 | 0.060 |
Why?
|
Polyamines | 1 | 2004 | 132 | 0.060 |
Why?
|
Decision Making | 1 | 2017 | 3890 | 0.060 |
Why?
|
Enzyme Inhibitors | 2 | 2005 | 3703 | 0.060 |
Why?
|
Anticoagulants | 1 | 2019 | 4830 | 0.060 |
Why?
|
Contrast Media | 1 | 2017 | 5276 | 0.060 |
Why?
|
Pyrimidines | 2 | 2006 | 2978 | 0.060 |
Why?
|
Young Adult | 10 | 2020 | 57629 | 0.060 |
Why?
|
Risk Assessment | 6 | 2020 | 23783 | 0.060 |
Why?
|
Cyclodextrins | 1 | 2003 | 64 | 0.060 |
Why?
|
Stroke Volume | 1 | 2017 | 5443 | 0.050 |
Why?
|
Logistic Models | 4 | 2019 | 13277 | 0.050 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2005 | 430 | 0.050 |
Why?
|
Patient Readmission | 1 | 2017 | 3288 | 0.050 |
Why?
|
Ribonucleotide Reductases | 1 | 2003 | 76 | 0.050 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2012 | 1199 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1689 | 0.050 |
Why?
|
Adolescent | 7 | 2020 | 86765 | 0.050 |
Why?
|
Myocardial Ischemia | 1 | 2013 | 2151 | 0.050 |
Why?
|
Bone Transplantation | 2 | 2018 | 913 | 0.050 |
Why?
|
Hemeproteins | 1 | 2002 | 61 | 0.050 |
Why?
|
Esters | 1 | 2003 | 211 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 723 | 0.050 |
Why?
|
Protoporphyrins | 1 | 2002 | 165 | 0.050 |
Why?
|
Cohort Studies | 6 | 2022 | 40984 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 10198 | 0.050 |
Why?
|
Anxiety | 1 | 2016 | 4456 | 0.050 |
Why?
|
Postoperative Period | 2 | 2018 | 1806 | 0.050 |
Why?
|
Hexokinase | 2 | 1992 | 125 | 0.050 |
Why?
|
Gene Amplification | 1 | 2006 | 1077 | 0.050 |
Why?
|
Hypercalcemia | 1 | 2024 | 415 | 0.050 |
Why?
|
Equipment Design | 2 | 2020 | 3510 | 0.050 |
Why?
|
Nanostructures | 1 | 2006 | 547 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2790 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15130 | 0.050 |
Why?
|
Materials Testing | 2 | 2020 | 854 | 0.050 |
Why?
|
Triazoles | 1 | 2006 | 906 | 0.050 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2005 | 679 | 0.040 |
Why?
|
Models, Biological | 2 | 2006 | 9449 | 0.040 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2006 | 612 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2017 | 8931 | 0.040 |
Why?
|
Reference Values | 2 | 2017 | 4897 | 0.040 |
Why?
|
Colombia | 1 | 2020 | 271 | 0.040 |
Why?
|
Drug Carriers | 1 | 2004 | 697 | 0.040 |
Why?
|
Protein Structure, Tertiary | 4 | 2007 | 3786 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2021 | 321 | 0.040 |
Why?
|
Lymphoma | 2 | 2019 | 1887 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4550 | 0.040 |
Why?
|
Albumins | 1 | 2021 | 565 | 0.040 |
Why?
|
Mutation | 2 | 2018 | 29705 | 0.040 |
Why?
|
Recovery of Function | 2 | 2020 | 2921 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2020 | 294 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2006 | 1373 | 0.040 |
Why?
|
Vascular Patency | 1 | 2021 | 901 | 0.040 |
Why?
|
Coronary Angiography | 2 | 2020 | 4543 | 0.040 |
Why?
|
Cell Line | 6 | 2008 | 15633 | 0.040 |
Why?
|
Italy | 1 | 2020 | 837 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1600 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12796 | 0.040 |
Why?
|
Hepacivirus | 1 | 2005 | 1330 | 0.040 |
Why?
|
Protein Conformation | 1 | 2006 | 3956 | 0.040 |
Why?
|
Arthrodesis | 1 | 2019 | 185 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11586 | 0.040 |
Why?
|
Swine, Miniature | 1 | 2020 | 954 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2003 | 1179 | 0.040 |
Why?
|
Molecular Conformation | 3 | 2003 | 549 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3308 | 0.040 |
Why?
|
Apoptosis | 1 | 2013 | 9429 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2019 | 343 | 0.040 |
Why?
|
Tomography, Optical Coherence | 2 | 2020 | 2840 | 0.040 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 2789 | 0.040 |
Why?
|
Sacrum | 1 | 2019 | 280 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20348 | 0.040 |
Why?
|
Depression | 1 | 2016 | 7917 | 0.040 |
Why?
|
Folic Acid | 1 | 2003 | 1299 | 0.030 |
Why?
|
Aftercare | 1 | 2023 | 914 | 0.030 |
Why?
|
Binding Sites | 4 | 2007 | 6028 | 0.030 |
Why?
|
Florida | 1 | 2017 | 419 | 0.030 |
Why?
|
Radiography | 2 | 2019 | 6964 | 0.030 |
Why?
|
Phosphorylation | 2 | 2006 | 8315 | 0.030 |
Why?
|
Fractures, Stress | 1 | 2018 | 192 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2266 | 0.030 |
Why?
|
Climate Change | 1 | 2022 | 481 | 0.030 |
Why?
|
Operating Rooms | 1 | 2022 | 784 | 0.030 |
Why?
|
Embolism, Fat | 1 | 2015 | 47 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 2214 | 0.030 |
Why?
|
Odds Ratio | 2 | 2019 | 9701 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2012 | 1774 | 0.030 |
Why?
|
Patients | 1 | 2022 | 904 | 0.030 |
Why?
|
Fracture Fixation | 1 | 2017 | 362 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1757 | 0.030 |
Why?
|
Artificial Limbs | 1 | 2016 | 119 | 0.030 |
Why?
|
Posture | 1 | 2019 | 952 | 0.030 |
Why?
|
Fracture Healing | 1 | 2017 | 436 | 0.030 |
Why?
|
Pelvis | 1 | 2019 | 736 | 0.030 |
Why?
|
Decompression, Surgical | 1 | 2019 | 595 | 0.030 |
Why?
|
Drug Resistance | 1 | 2020 | 1609 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 2 | 2006 | 456 | 0.030 |
Why?
|
Fracture Fixation, Intramedullary | 1 | 2016 | 159 | 0.030 |
Why?
|
Cricetinae | 2 | 2008 | 2421 | 0.030 |
Why?
|
Pulmonary Embolism | 2 | 2019 | 2515 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2016 | 984 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 35916 | 0.030 |
Why?
|
Models, Animal | 1 | 2020 | 2115 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2635 | 0.030 |
Why?
|
Cell Survival | 3 | 2007 | 5771 | 0.030 |
Why?
|
Aortic Valve | 1 | 2023 | 1991 | 0.030 |
Why?
|
Biopsy, Fine-Needle | 1 | 2018 | 1108 | 0.030 |
Why?
|
Hexosephosphates | 1 | 1992 | 26 | 0.030 |
Why?
|
Accidents, Traffic | 1 | 2018 | 812 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2093 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2019 | 20843 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2277 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2017 | 1510 | 0.020 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 1572 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2013 | 660 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 2906 | 0.020 |
Why?
|
Protein Transport | 2 | 2006 | 1964 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2924 | 0.020 |
Why?
|
Hemoglobins | 1 | 2017 | 1510 | 0.020 |
Why?
|
Multiple Myeloma | 2 | 2019 | 5110 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 2 | 2007 | 1898 | 0.020 |
Why?
|
Radiotherapy | 1 | 2017 | 1506 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12455 | 0.020 |
Why?
|
Benzamides | 2 | 2006 | 1364 | 0.020 |
Why?
|
Shoulder Joint | 1 | 2017 | 729 | 0.020 |
Why?
|
Venous Thrombosis | 1 | 2019 | 1278 | 0.020 |
Why?
|
Swine | 1 | 2020 | 5883 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3412 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4110 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2012 | 568 | 0.020 |
Why?
|
Mass Spectrometry | 2 | 2008 | 2176 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2016 | 1800 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3914 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2005 | 5594 | 0.020 |
Why?
|
Observer Variation | 1 | 2015 | 2579 | 0.020 |
Why?
|
Diarrhea Viruses, Bovine Viral | 1 | 2008 | 6 | 0.020 |
Why?
|
Tetrazolium Salts | 1 | 2008 | 92 | 0.020 |
Why?
|
Chromatography, Thin Layer | 1 | 2008 | 215 | 0.020 |
Why?
|
Mannich Bases | 1 | 2007 | 2 | 0.020 |
Why?
|
Databases, Factual | 2 | 2017 | 7898 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2017 | 4637 | 0.020 |
Why?
|
Aspirin | 1 | 2020 | 3341 | 0.020 |
Why?
|
Thrombophlebitis | 1 | 2009 | 290 | 0.020 |
Why?
|
Prevalence | 2 | 2017 | 15506 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 646 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1178 | 0.020 |
Why?
|
Surgical Wound Dehiscence | 1 | 2009 | 216 | 0.020 |
Why?
|
Entropy | 1 | 2008 | 207 | 0.020 |
Why?
|
Skin Transplantation | 1 | 2012 | 1025 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2008 | 457 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3585 | 0.020 |
Why?
|
Enterovirus | 1 | 2007 | 65 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5858 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9236 | 0.020 |
Why?
|
Magnesium Hydroxide | 1 | 2006 | 9 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8443 | 0.020 |
Why?
|
Adsorption | 1 | 2006 | 195 | 0.020 |
Why?
|
Aluminum Hydroxide | 1 | 2006 | 55 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2008 | 3752 | 0.020 |
Why?
|
Animals | 7 | 2020 | 166802 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 494 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 878 | 0.020 |
Why?
|
Viral Nonstructural Proteins | 1 | 2007 | 224 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2007 | 1137 | 0.020 |
Why?
|
Quantitative Structure-Activity Relationship | 1 | 2005 | 27 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 1341 | 0.020 |
Why?
|
Isoleucine | 1 | 2005 | 110 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2015 | 1833 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2008 | 717 | 0.020 |
Why?
|
Candida | 1 | 2006 | 165 | 0.020 |
Why?
|
Sciatic Nerve | 1 | 2009 | 608 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2007 | 412 | 0.020 |
Why?
|
Kidney | 1 | 2020 | 6983 | 0.020 |
Why?
|
Diffusion | 1 | 2006 | 810 | 0.020 |
Why?
|
Spectrum Analysis | 1 | 2007 | 451 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2024 | 5726 | 0.020 |
Why?
|
Threonine | 1 | 2005 | 271 | 0.020 |
Why?
|
Models, Statistical | 1 | 2019 | 5049 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2013 | 6112 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11007 | 0.010 |
Why?
|
Death, Sudden, Cardiac | 1 | 2012 | 1557 | 0.010 |
Why?
|
Surgical Flaps | 1 | 2012 | 1657 | 0.010 |
Why?
|
Pneumonia | 1 | 2015 | 2121 | 0.010 |
Why?
|
Chemistry, Physical | 1 | 2003 | 154 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4271 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12137 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 2003 | 508 | 0.010 |
Why?
|
Health Status | 1 | 2016 | 4050 | 0.010 |
Why?
|
Solvents | 1 | 2004 | 293 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12898 | 0.010 |
Why?
|
Nucleosides | 1 | 2003 | 130 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2014 | 3050 | 0.010 |
Why?
|
Dogs | 1 | 2007 | 3840 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2008 | 1346 | 0.010 |
Why?
|
Escherichia coli | 2 | 1992 | 4183 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6781 | 0.010 |
Why?
|
Cattle | 1 | 2008 | 3848 | 0.010 |
Why?
|
Child | 2 | 2020 | 78998 | 0.010 |
Why?
|
Wound Healing | 1 | 2012 | 2772 | 0.010 |
Why?
|
Molecular Mimicry | 1 | 2002 | 199 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10797 | 0.010 |
Why?
|
Surface Properties | 1 | 2004 | 1154 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9101 | 0.010 |
Why?
|
Myocardium | 1 | 2013 | 4648 | 0.010 |
Why?
|
Thiazoles | 1 | 2008 | 1505 | 0.010 |
Why?
|
Electrocardiography | 1 | 2014 | 6379 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8420 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2009 | 3489 | 0.010 |
Why?
|
Ligands | 1 | 2007 | 3274 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 2002 | 1433 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18297 | 0.010 |
Why?
|
Stroke | 2 | 2012 | 9879 | 0.010 |
Why?
|
Ultrasonography | 1 | 2012 | 5918 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1992 | 1747 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8362 | 0.010 |
Why?
|
Skin | 1 | 2012 | 4421 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 1991 | 3803 | 0.010 |
Why?
|
Proteins | 1 | 1991 | 6015 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25535 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7995 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2008 | 4279 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9273 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7399 | 0.010 |
Why?
|
Computational Biology | 1 | 2005 | 3492 | 0.010 |
Why?
|
Placenta | 2 | 1992 | 1688 | 0.010 |
Why?
|
Chromatography, Ion Exchange | 1 | 1992 | 297 | 0.010 |
Why?
|
Mice | 2 | 2013 | 80543 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11830 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2006 | 5163 | 0.010 |
Why?
|
Base Sequence | 2 | 1992 | 12432 | 0.010 |
Why?
|
Oxygen | 1 | 2002 | 4171 | 0.010 |
Why?
|
Catalysis | 1 | 1992 | 774 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1992 | 13410 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1991 | 1543 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1992 | 17591 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1992 | 811 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1992 | 1540 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16736 | 0.000 |
Why?
|
Enzyme Activation | 1 | 1992 | 3597 | 0.000 |
Why?
|
Cloning, Molecular | 1 | 1991 | 4166 | 0.000 |
Why?
|
HIV-1 | 1 | 2003 | 6827 | 0.000 |
Why?
|
Blotting, Western | 1 | 1992 | 5035 | 0.000 |
Why?
|
Kinetics | 1 | 1992 | 6352 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3781 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1992 | 6509 | 0.000 |
Why?
|
DNA | 1 | 1992 | 7215 | 0.000 |
Why?
|
Pregnancy | 1 | 1992 | 29439 | 0.000 |
Why?
|